Clinical Trial Update: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of talazoparib in Japanese patients with advanced solid tumors has completed, with results posted in 2022 detailing initial safety and pharmacokin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2022-03-10